Orchid Pharma Limited has announced an investor roadshow scheduled for April 10, 2026, in Gurugram. The pharmaceutical company informed the National Stock Exchange of India Limited and BSE Limited about this development on April 07, 2026, under Regulation 30 of SEBI listing requirements.

Roadshow Details

The investor roadshow will feature Mr. Mridul Dhanuka, Whole Time Director of Orchid Pharma Limited, who will participate in the scheduled meeting with investors.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The company has emphasized that no unpublished price sensitive information is proposed to be shared during the investor meet.

Important Considerations

Orchid Pharma Limited has noted that the roadshow schedule may undergo changes due to unforeseen exigencies on the part of investors or the company. Any such changes will be communicated accordingly. The notification was signed by Manish Dhanuka, Managing Director, on April 07, 2026.

Orchid Pharma Limited has received a credit rating downgrade from CARE Ratings Limited, with the agency revising the company's long-term bank facilities rating to CARE BBB+ with Stable outlook from the previous CARE A- rating. The rating action, communicated through a letter dated April 1, 2026, affects the company's total banking facilities worth Rs. 366.50 crore.

Rating Action Details

CARE Ratings has taken comprehensive rating actions across Orchid Pharma's various banking facilities. The rating agency downgraded long-term facilities while reaffirming short-term ratings and removed all facilities from Rating Watch with Developing Implications.

Facility Breakdown

The total banking facilities of Rs. 366.50 crore are distributed across multiple banks and facility types. HDFC Bank Limited provides the majority of the facilities, including term loans of Rs. 142.50 crore with a tenor of 6 years including a 12-month moratorium period.

Long-Term Facilities (Rs. 207.50 crore)

• Term Loans: Rs. 142.50 crore from HDFC Bank with repayment in 20 equal consecutive quarterly instalments
• Cash Credit: Rs. 65.00 crore from HDFC Bank

Short-Term Facilities (Rs. 84.00 crore)

• Non-Fund Based Limits: Rs. 84.00 crore from HDFC Bank for LC with sublimits for SBLG/BG

Combined Facilities (Rs. 75.00 crore)

• Fund/Non-Fund Based: Rs. 75.00 crore from Yes Bank for CC/PCFC/WCDL/LC/BG/LCBD

Basis for Rating Review

CARE Ratings based its rating committee review on several key factors including the company's operational and financial performance for FY25 (Audited) and 9MFY26 (Provisional). The rating action also considered the final order on scheme of amalgamation being reserved for final pronouncement by NCLT and the completion of acquisition of assets related to own molecule.

Regulatory Compliance

The company has informed the stock exchanges about this rating update in compliance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was sent to both NSE and BSE on April 2, 2026, with the complete CARE rating letter attached for reference.